May 23, 2018 | Anti-METH antibody, IXT-m200, General News
– IXT-m200 is InterveXion’s lead program in treating methamphetamine abuse – STAMPOUT: Phase 2 proof-of-concept trial to test effects of first-in-class anti-methamphetamine antibody in methamphetamine users Little Rock, AR – InterveXion Therapeutics, a...
May 10, 2018 | Anti-METH antibody, IXT-m200, General News
STAMPOUT: Phase 2 proof-of-concept trial to test effects of first-in-class anti-methamphetamine antibody in methamphetamine users Little Rock, AR – InterveXion announces the enrollment of the first patient in STAMPOUT, the first trial in methamphetamine users of the...
Recent Comments